Analog Devices, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Analog Devices, Inc. trades at $389.54 (market cap $187.67B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B). The key difference: Analog Devices, Inc. is far larger — about 71.1× Amylx Pharmaceuticals Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ADI | AMLX | |
|---|---|---|
Market Cap | $187.67B | $2.64B |
Sector | Technology | Health |
52-Week High | $445.48 | $24.19 |
52-Week Low | $225.20 | $7.82 |
Enterprise Value | $192.92B | $2.39B |
Dividend Yield | 1.14% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Trailing returns across standard periods
Latest headlines on both assets
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →